OTCM
BSEM
Market cap44mUSD
Oct 08, Last price
2.64USD
1D
10.46%
1Q
-28.46%
Jan 2017
-73.73%
IPO
-100.00%
Name
Biostem Technologies Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Key people
Thomas Dugan
Independent Non-Executive Chairman of the Board · since 2023
Michael Fortunato
Chief Financial Officer · since 2022
Barry Hassett
Chief Commercial Officer · since 2026
Shawn Mccarrey
Chief Commercial Officer · since 2024
Jason Matuszewski
Chief Executive Officer, Director · since 2019
Andrew Van Vurst
Chief Operating Officer, Director · since 2016
Patrick Daly
Independent Director · since 2023
Brandon Poe
Independent Director · since 2022
Kenneth Warrington
Independent Director · since 2022
Legal address
C/O Van Vurst, Andrew
2836 Center Port Circle
Pompano Beach, FL 33064
US
2836 Center Port Circle
Pompano Beach, FL 33064
US
Headquarters
2836 Center Port Circle
Pompano Beach, FL 33064
US
Pompano Beach, FL 33064
US
Previous name
Caribbean Casino & Gaming Corporation
Previous name
Caribbean International Holdings, Inc.
Previous name
BioStem Technologies, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||